Acurx Pharmaceuticals (FRA:3ZO0) Short-Term Debt: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3ZO0 Acurx Pharmaceuticals Inc FRA:3ZO0
37 GF Score
Price €5.09
View Full Analysis

What is Acurx Pharmaceuticals Short-Term Debt?

Acurx Pharmaceuticals FRA:3ZO0 37 Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:3ZO0 with a GF Score™ of 37/100.

Acurx Pharmaceuticals's Short-Term Debt for the quarter that ended in Jun. 2026 was €0.00 Mil.

Acurx Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Acurx Pharmaceuticals Short-Term Debt Related Terms

Acurx Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Acurx Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acurx Pharmaceuticals Short-Term Debt Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Acurx Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3ZO0
37GF Score
Acurx Pharmaceuticals Inc FRA:3ZO0
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
Acurx Pharmaceuticals (FRA:3ZO0) has a Short-Term Debt of €0.00 Mil as of Jun. 2026.
Is Acurx Pharmaceuticals' Short-Term Debt too high?
Acurx Pharmaceuticals' current Short-Term Debt is €0.00 Mil. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' Short-Term Debt compare to ENVB and HCWB?
Acurx Pharmaceuticals' Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Acurx Pharmaceuticals's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (FRA:3ZO0) has a current Short-Term Debt of €0.00 Mil. The current Short-Term Debt is €0.00 Mil. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Acurx Pharmaceuticals (FRA:3ZO0), the current Short-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acurx Pharmaceuticals Business Description

Other Exchanges ACXP:USA
Address 259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score

Get the complete analysis for FRA:3ZO0

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09
Price